10-Q: IFF Reports Q1 2026 Results, Navigates Portfolio Changes

International Flavors & Fragrances Inc. (IFF) reported Q1 2026 results, showing a decrease in net sales but an increase in comparable currency neutral sales, alongside a significant goodwill impairment charge in the prior year.

Summary

• Net sales for the first quarter of 2026 were $2.741 billion, a decrease of 4% from $2.843 billion in the first quarter of 2025.
• On a comparable currency neutral basis, net sales increased by 3%.
• Gross profit decreased by 2% to $1.018 billion, with a gross margin of 37.1% compared to 36.4% in the prior year.
• Operating profit was $273 million, a significant improvement from an operating loss of $903 million in Q1 2025, which was impacted by a goodwill impairment charge.
• Net income attributable to IFF shareholders was $169 million, or $0.66 per diluted share, a substantial improvement from a net loss of $1.018 billion, or ($3.98) per diluted share, in Q1 2025.
• The company completed the divestiture of its Soy Crush, Concentrates, and Lecithin business on March 2, 2026.
• The company had no outstanding borrowings under its $2 billion Revolving Credit Facility as of March 31, 2026.
• The company's net debt to credit adjusted EBITDA ratio was 2.53 to 1.0 as of March 31, 2026, below the covenant limit.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a mixed but generally positive report, with strong operational improvements and growth in key segments, despite a reported sales decline due to divestitures and currency impacts.

Positives

• Comparable currency neutral sales increased by 3%, indicating underlying business growth.
• Operating profit improved significantly to $273 million from a loss of $903 million in the prior year.
• Net income turned positive at $169 million, a substantial recovery from a net loss of $1.018 billion in Q1 2025.
• Gross margin improved to 37.1% from 36.4% in the prior year.
• Health & Biosciences segment showed strong sales growth of 10% (5% on a comparable currency neutral basis).
• Taste and Food Ingredients segments also reported positive sales growth.
• The company has no outstanding borrowings under its $2 billion Revolving Credit Facility.
• The company is in compliance with its debt covenants, with a net debt to credit adjusted EBITDA ratio of 2.53 to 1.0.

Negatives

• Reported net sales decreased by 4% to $2.741 billion.
• Cost of sales decreased by 5%, but the decrease in sales was more significant.
• Restructuring and other charges decreased, but were still present at $6 million.
• The Scent segment's comparable currency neutral Adjusted Operating EBITDA decreased by 2% due to unfavorable net pricing.
• The Pharma Solutions segment had no sales in Q1 2026 due to divestiture.

Risks

• Future impairment of the Taste reporting unit could occur if key assumptions in fair value testing change.
• Potential for future material adverse effects on operations and financial results due to various risk factors including demand trends, competitive dynamics, execution of strategic transformation, supply chain disruptions, and geopolitical developments.
• The company is subject to ongoing investigations related to fragrance businesses and potential anti-competitive conduct, which could result in significant fines or payments.
• The company is unable to predict the outcome or potential impact of ongoing litigation and investigations on its results of operations, liquidity, or financial condition.

Future Outlook

The company expects capital spending in 2026 to be approximately 6% of sales. Management believes that cash flows from operations, proceeds from planned divestitures, and availability under existing credit facilities will be sufficient to meet investing and financing needs, including debt service requirements.

Management Comments

• Sales performance by segment was as follows: Taste increased 5% (2% comparable currency neutral), Food Ingredients increased 5% (3% comparable currency neutral), Health & Biosciences increased 10% (5% comparable currency neutral), and Scent increased 6% (1% comparable currency neutral).
• The decrease in S&A expenses was primarily driven by lower consulting fees incurred in relation to business divestitures.
• The decrease in interest expense was due to lower debt outstanding.
• The increase in cash flows from operating activities during 2026 was primarily driven by a smaller incentive compensation payout made in 2026 related to 2025 results compared to the prior year, and an increase in inventories in the prior year.
• The increase in cash flows provided by investing activities was primarily driven by net proceeds received from business divestitures during the three months ended March 31, 2026.

Industry Context

StockSavvy.ai notes that IFF's performance reflects broader industry trends of portfolio optimization and the impact of currency fluctuations. The company's focus on growth in Health & Biosciences and Taste segments, while managing costs and divestitures, is a common strategy in the specialty ingredients sector.

Comparison to Industry Standards

• IFF's gross margin of 37.1% is within the typical range for large flavor and fragrance companies, though direct comparisons are difficult without specific competitor data for the same period.
• The company's R&D expenses as a percentage of sales (6.1%) are consistent with industry norms for innovation-driven companies in this sector.
• The significant goodwill impairment charge in the prior year ($1.153 billion) highlights the challenges of integrating large acquisitions, a common theme in the industry, particularly following the Frutarom acquisition.
• The company's strategy of divesting non-core assets and focusing on core segments is a trend seen across the chemical and ingredients industry, aiming for higher growth and margin businesses.

Legal Proceedings

• Securities class action lawsuit filed in Israel alleging false and misleading statements related to the Frutarom acquisition and improper payments; settlement approved by the court in November 2025.
• Claim filed in Israel against former Frutarom executives challenging a $20 million bonus due to alleged breach of fiduciary duty.
• Multiple putative class action lawsuits filed in Canada and the United States alleging violations of competition laws related to fragrance products; IFF entered into a settlement agreement for U.S. direct purchasers for $26 million, and has entered into settlement agreements with indirect purchaser and end-user plaintiffs.
• Additional class action complaint filed in New Jersey on behalf of purchasers of consumer goods containing fragrance products purchased outside the United States.
• Investigations by European Commission, UK CMA, Swiss Competition Commission, and US DOJ into potential anti-competitive conduct in fragrance businesses; DOJ investigation closed, but other investigations are ongoing.
• Investigations in Singapore and India related to employment practices in the fragrance industry.

Stakeholder Impact

• Shareholders may see improved value through positive operational performance and share repurchases, but litigation and investigations pose ongoing risks.
• Employees may be impacted by ongoing restructuring and productivity programs.
• Customers may benefit from continued innovation and product development, particularly in the growing Health & Biosciences and Taste segments.
• Creditors are protected by the company's strong liquidity position and compliance with debt covenants.

Next Steps

• Continue to execute on the productivity enhancement program aimed at improving productivity and optimizing organizational footprint, with substantial completion expected by December 31, 2026.
• Continue to manage portfolio optimization initiatives, including the ongoing evaluation of strategic alternatives for the Food Ingredients segment.
• Repatriate cash from international operations to fund financial obligations in the U.S., managing associated tax implications.
• Continue to repurchase shares under the $500 million share repurchase program.
• Monitor and manage ongoing investigations and litigation, which could materially impact results.

Key Dates

Recommendation

IFF's Q1 2026 results show a significant turnaround from the prior year's loss, driven by operational improvements and strategic divestitures. The comparable currency neutral sales growth and improved profitability are positive indicators. However, ongoing litigation and investigations, along with the inherent cyclicality and competitive pressures in the flavors and fragrances industry, warrant a cautious approach. The company's strong liquidity and compliance with debt covenants provide a stable foundation. A 'hold' recommendation reflects the balance between operational recovery and the persistent risks associated with legal and regulatory matters.

Keywords

International Flavors & Fragrances, IFF, Quarterly Report, Form 10-Q, Financial Results, Sales, Profit, Goodwill Impairment, Divestiture, Credit Facility, Leverage Ratio, Taste, Food Ingredients, Health & Biosciences, Scent